Brief: Monte Rosa Therapeutics announces FDA clearance of investigational new drug application for MRT-2359, GSPT1-directed molecular glue degrader
06/09/2022 12:45
Sept 6 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR MRT-2359, A
GSPT1-DIRECTED MOLECULAR GLUE DEGRADER
* MONTE ROSA THERAPEUTICS - ON TRACK WITH INITIATING A PHASE
1/2
CLINICAL TRIAL OF MRT-2359 IN PATIENTS WITH MYC-DRIVEN SOLID
TUMORS, INCLUDING LUNG CANCER
* MONTE ROSA THERAPEUTICS INC - EXPECTS TO DOSE FIRST
PATIENT IN
Q4 OF 2022
Source text for Eikon: ID:nGNX2kyzZX
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million